Participation in clinical trials may help overcome health disparities in the treatment of advanced or recurrent ovarian cancer, according to a presentation at the SGO 2018 Annual Meeting on Women’s Cancer. READ MORE
Researchers compared intensity-modulated radiation therapy versus conventional radiation therapy by evaluating acute toxicities in the GI and GU systems.
Prolonging platinum-free interval by introducing non-platinum-based chemotherapy may actually worsen efficacy outcomes in patients with recurrent ovarian cancer.
Participation in clinical trials may help overcome health disparities in the treatment of advanced or recurrent ovarian cancer, according to a presentation at the SGO 2018 Annual Meeting on Women’s Cancer.
Health care providers and patients have identified a need for further resources to support survivorship care in gynecologic oncology, according to a presentation given at the 2018 ASCO Cancer Survivorship Symposium.
The US Preventive Services Task Force advises against ovarian cancer screening in asymptomatic women not known to be at high risk, concluding that the potential harms of screening outweigh the benefits.
A study soon to published found that palliative care for patients with ovarian cancer was often provided later than recommended in national guidelines.
Research in Review
New research questions the value of risk-reducing mastectomy within five years of ovarian cancer diagnosis in patients with BRCA mutations.
Patients receiving treatment for ovarian cancer experienced a significant out-of-pocket financial burden, due largely to cost disparities across treatment types and a lack of definitive treatment options.
Researchers used Surveillance, Epidemiology, and End Results registry data to review the costs associated with treatment plans consistent with NCCN guidelines.
The National Comprehensive Cancer Network has updated their guidelines for the treatment of ovarian cancer, including therapy for stage II-IV disease and persistent disease.
The American College of Obstetricians and Gynecologists has recently updated its clinical guidelines for the management of hereditary breast and ovarian cancer syndrome.